Video Experimental Relacionado
Updated: Sep 10, 2025
09:39
A Platform of Anti-biofilm Assays Suited to the Exploration of Natural Compound Libraries
Published on: December 27, 2016
17.9K
Diferentes derivados del análogo de Plumbagin: estudios de biodisponibilidad y toxicidad
Souparnika Thekkumkara1, Arenbenla Longchar1, Baskar Venkidasamy2
1Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS) Mangaluru Karnataka India.
Food science & nutrition
|August 22, 2025
Resumen
Plumbagin, un compuesto de Plumbago zeylanica, muestra potencial para el tratamiento de varias enfermedades debido a sus propiedades anticancerígenas y antimicrobianas. Sin embargo, los desafíos con la biodisponibilidad y la toxicidad requieren más investigación para un uso clínico seguro.
Área de la Ciencia:
- Farmacología
- Productos naturales Química
Sus antecedentes:
- Plumbagin, una naftokinona de la especie Plumbago, exhibe diversas actividades farmacológicas.
- La medicina tradicional utiliza el Plumbago zeylanica para varias dolencias.
Objetivo del estudio:
- Revisar el potencial terapéutico y las limitaciones de plumbagin.
- Explorar estrategias para superar los desafíos de plumbagin en aplicaciones clínicas.
Principales métodos:
- Revisión de la literatura de los estudios existentes sobre las propiedades, la biodisponibilidad y la toxicidad de plumbagin.
- Análisis de la investigación en curso en la administración de fármacos, la modificación química y la terapia combinada.
Principales resultados:
- Plumbagin muestra prometedores efectos anticancerígenos, antimalarianos, antidiabéticos y antimicrobianos.
- La baja solubilidad, la inestabilidad metabólica y la toxicidad (citotoxicidad, toxicidad orgánica) limitan el uso clínico de plumbagin.
Conclusiones:
- Plumbagin y sus derivados tienen una promesa terapéutica significativa, especialmente en oncología y enfermedades infecciosas.
- Abordar los problemas de biodisponibilidad y toxicidad mediante estrategias avanzadas es crucial para la traducción clínica.
- Es esencial realizar más investigaciones clínicas para comprender plenamente el valor terapéutico de plumbagin y garantizar la seguridad del paciente.
Videos de Conceptos Relacionados
01:13Bioavailability: Overview
3.1K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
3.1K
01:23Factors Influencing Bioavailability: First-Pass Elimination
7.0K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
7.0K
01:16Drug Biotransformation: Overview
2.9K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.9K
01:16Bioequivalence: Overview
1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K
01:24Factors Influencing Drug Absorption: Presystemic Elimination
340
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
340
01:30Prodrugs
2.8K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.8K